Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism.
Anesthesiology. 2010 Jan; 112(1):73-85
Anesthesiology. 2010 Jan; 112(1):73-85
Michael Irwin and Zhengyuan Xia, University of Hong Kong, Hong Kong. F1000 Anesthesiology & Pain Management
09 Mar 2010 | New Finding
This is an interesting study demonstrating that brief administration of isoflurane during the late phase of ischemia and early phase of reperfusion (postconditioning) reduces myocardial damage and improves cardiac function by preventing mitochondrial permeability transition (MPT) pore opening. It is the first study showing that the isoflurane postconditioning effect is endothelial nitric oxide synthase (eNOS)-dependent. Nitric oxide produced by eNOS serves not only as a trigger but also as a mediator of isoflurane postconditioning cardioprotection against ischemia/reperfusion (I/R) injury.
The authors used multiple approaches incorporating both in vivo and ex vivo models of myocardial I/R to confirm the cardioprotection of isoflurane postconditioning. In addition, a myocardial I/R model was induced using eNOS knock-out mice to confirm the mechanism of isoflurane postconditioning. This is a complicated and important study confirming the effectiveness and mechanism of volatile anesthetic isoflurane postconditioning. The study highlights the significance of eNOS in volatile anesthetic postconditioning. In diabetes, especially the diabetic myocardium, eNOS signaling is impaired, in part due to the deficiency of the eNOS cofactor tetrahydrobiopterin (BH4). This may cause eNOS uncoupling and decease nitric oxide availability. This could be why isoflurane preconditioning cardioprotection is compromised or lost in diabetes. Another research group recently showed that isoflurane postconditioning is impaired by hyperglycemia {1}. This later study by Ge et al. is another advancement in understanding the mechanism of isoflurane postconditioning. Further study is needed using chronic animal models of diabetes to help clarify the possible clinical relevance of these findings regarding volatile anesthetic postconditioning.
References: {1} Amour et al. Anesthesiology 2010, 112:576-85 [PMID:20124983].
Xia Z, Irwin M: "This is an interesting study demonstrating that brief administration of isoflurane during the late phase..." Evaluation of: [Ge ZD et al. Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism. Anesthesiology. 2010 Jan; 112(1):73-85; doi: 10.1097/ALN.0b013e3181c4a607]. Faculty of 1000, 09 Mar 2010. F1000.com/2405956#eval2039054
Short form
Xia Z, Irwin M: 2010. F1000.com/2405956#eval2039054
Faculty of 1000 evaluations, dissents and comments for [Ge ZD et al. Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism. Anesthesiology. 2010 Jan; 112(1):73-85; doi: 10.1097/ALN.0b013e3181c4a607]. Faculty of 1000, 09 Mar 2010. F1000.com/2405956
Short form
Faculty of 1000: 2010. F1000.com/2405956
BACKGROUND: The role of endothelial nitric oxide synthase (eNOS) in isoflurane postconditioning (IsoPC)-elicited cardioprotection is poorly understood. The authors addressed this issue using eNOS mice.
METHODS: In vivo or Langendorff-perfused mouse hearts underwent 30 min of ischemia followed by 2 h of reperfusion in the presence and absence of postconditioning produced with isoflurane 5 min before and 3 min after reperfusion. Ca+-induced mitochondrial permeability transition (MPT) pore opening was assessed in isolated mitochondria. Echocardiography was used to evaluate ventricular function.
RESULTS: Postconditioning with 0.5, 1.0, and 1.5 minimum alveolar concentrations of isoflurane decreased infarct size from 56 +/- 10% (n = 10) in control to 48 +/- 10%, 41 +/- 8% (n = 8, P < 0.05), and 38 +/- 10% (n = 8, P < 0.05), respectively, and improved cardiac function in wild-type mice. Improvement in cardiac function by IsoPC was blocked by N-nitro-L-arginine methyl ester (a nonselective nitric oxide synthase inhibitor) administered either before ischemia or at the onset of reperfusion. Mitochondria isolated from postconditioned hearts required significantly higher in vitro Ca+ loading than did controls (78 +/- 29 microm vs. 40 +/- 25 microm CaCl2 per milligram of protein, n = 10, P < 0.05) to open the MPT pore. Hearts from eNOS mice displayed no marked differences in infarct size, cardiac function, and sensitivity of MPT pore to Ca+, compared with wild-type hearts. However, IsoPC failed to alter infarct size, cardiac function, or the amount of Ca+ necessary to open the MPT pore in mitochondria isolated from the eNOS hearts compared with control hearts.
CONCLUSIONS: IsoPC protects mouse hearts from reperfusion injury by preventing MPT pore opening in an eNOS-dependent manner. Nitric oxide functions as both a trigger and a mediator of cardioprotection produced by IsoPC.
DOI: 10.1097/ALN.0b013e3181c4a607
PMID: 19996950
Aspect(s) of health care
Study population
Article Type
Sign in/get access to leave a comment.
No comments yet.